Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNC-remdesivir
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Potentially Other Routes
01
Overview
LNC-remdesivir is a **formulation of remdesivir that utilizes lipid nanoparticle (LNC) technology for drug delivery**. This modified version is designed to enhance the pharmacokinetic and pharmacodynamic properties of remdesivir, a nucleoside analog antiviral that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral RNA synthesis and replication. The base compound, remdesivir, is approved for the treatment of COVID-19 and acts by incorporating into viral RNA chains and causing delayed chain termination. The use of lipid nanoparticles as a delivery vehicle aims to improve tissue targeting, bioavailability, and possibly to enable non-intravenous administration routes. As a novel formulation, LNC-remdesivir may be under investigation and not yet approved for clinical use.
- Brand names
- LNC-remdesivir
- Other names
- LNC-remdesivir
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on LNC-remdesivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNC-remdesivir.